Vivos Therapeutics Announces Exercise Of Warrants For ~$4M Aggregate Gross Proceeds
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics, Inc. (VVOS) announced the exercise of a common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $4.0 million for Vivos. The transaction involves the purchase of 980,393 shares at a revised price of $4.02 per share. Additionally, Vivos will issue two new unregistered warrants for a total of 1,470,592 shares at $5.05 per share. A.G.P./Alliance Global Partners is the financial advisor for the offering.
February 15, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics, Inc. has successfully exercised a warrant for gross proceeds of $4M, and issued new warrants for further capital. A.G.P./Alliance Global Partners is advising.
The exercise of the warrant and the subsequent issuance of new warrants for Vivos Therapeutics represents a positive financial development for the company, potentially strengthening its balance sheet and providing additional capital for operations and growth. The involvement of a reputable financial advisor, A.G.P./Alliance Global Partners, adds credibility to the transaction, likely instilling investor confidence.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100